RegIntel Ltd. A Regulatory Intelligence Consultancy During the 1990’s the top 10 pharmaceutical companies spent on average $802 million to bring a new drug to market; this represents an increase of about 100% every decade since the 1970’s. The growth in cost is primarily attributable to clinical development and a significant part of it is derived from increased government regulation. By optimising resources for collecting, analysing, and anticipating regulatory information and change, biopharmaceutical and medical device companies can not only save money, they can also add value to marketed products. A small investment in regulatory intelligence can yield benefits many times the initial cost. RegIntel ltd., an independent Irish-based consultancy, provides advice and analysis on licensing, business development, as well as regulatory intelligence and solutions thereof. Regintel is also interested in the kinds of business opportunities that arise from regulatory change, and is actively seeking opportunities in this area. Specific areas of interest include genomics, obesity and weight management, electronic patient reported outcomes, European and Canadian regulatory services, ediary technology, and validation. RegIntel was founded by Breffni Martin in December 2002. Email: bmartin@regintel.com Telephone: +353 42 9376973 Mobile +087 914 5363 Copyright © 2003, RegIntel Ltd.